Interview with "Laborjournal"

28. March 2022 In News

Interview with the magazine “Laborjournal”

Research and development without or with significantly less animal testing must be possible. We at Dynamic42 are convinced of this and at the same time on the way to realising this goal with the help of our organ-on-chip technology.

In an interview with the trade journal “Laborjournal”, our managing directors Martin Raasch and Knut Rennert explain how the Dynamic42 biotech chips work and how the “mini-organs” used contribute to reducing animal experiments.

The article also gives exciting insights into the background of our company and explains what our company name means.

Read the full interview in German: Laborjounal online: Nerdy names and runny noses

Recommendation: The magazine reported in more detail about our technology in the print edition. Laborjournal issue 03/22 (page 46/47)

Press Release | Tumour-on-chip model supports preclinical drug development on pancreatic cancer

Dynamic42 and Heinrich Heine University have developed a tumour-on-a-chip model that replicates the microenvironment of pancreatic ductal adenocarcinoma (PDAC). This 3D model allows for realistic drug testing and could accelerate the development of personalized therapies.

Press Release | Dynamic42 and research partners present three-organ system to reduce animal testing

Dynamic42, in collaboration with ESQlabs, Bayer, and the Placenta Lab, has developed an innovative three-organ system with the potential to reduce animal testing in pharmaceutical research.